Pregnancy may favour the development of severe autoimmune central diabetes insipidus in women with vasopressin cell antibodies: description of two cases
| Autor: | Annamaria De Bellis, Giuseppe Bellastella, A. Bizzarro, Ernesto Aitella, Domenico Cozzolino, Mariluce Barrasso, Sergio Di Martino, Katherine Esposito |
|---|---|
| Přispěvatelé: | Bellastella, Giuseppe, Bizzarro, Antonio, Aitella, E, Barrasso, M, Cozzolino, Domenico, Di Martino, S, Esposito, Katherine, DE BELLIS, Annamaria |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Vasopressin medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.disease_cause Autoimmune Disease Autoimmunity Autoimmune Diseases Endocrinology Pregnancy Internal medicine medicine Humans Deamino Arginine Vasopressin Subclinical infection Autoantibodies Autoimmune disease business.industry Incidence (epidemiology) Medicine (all) General Medicine medicine.disease Autoantibodie Arginine Vasopressin Diabetes Insipidus Neurogenic Diabetes insipidus Gestation Female business Human |
| Zdroj: | European journal of endocrinology. 172(3) |
| ISSN: | 1479-683X |
| Popis: | Recently, an increased incidence of central diabetes insipidus (CDI) in pregnancy, and less frequently in thepost partumperiod, has been reported, most probably favoured by some conditions occurring in pregnancy. This study was aimed at investigating the influence of pregnancy on a pre-existing potential/subclinical hypothalamic autoimmunity. We studied the longitudinal behaviour of arginine–vasopressin cell antibodies (AVPcAbs) and post-pituitary function in two young women with a positive history of autoimmune disease and presence of AVPcAbs, but without clinical CDI, and who became pregnant 5 and 7 months after our first observation. The behaviour of post-pituitary function and AVPcAbs (by immunofluorescence) was evaluated at baseline, during pregnancy and for 2 years after delivery. AVPcAbs, present at low/middle titres at baseline in both patients, showed a titre increase during pregnancy in one patient and after delivery in the other patient, with development of clinically overt CDI. Therapy with 1-deamino-8-d-arginine vasopressin (DDAVP) caused a prompt clinical remission. After a first unsuccessful attempt of withdrawal, the therapy was definitively stopped at the 6th and the 7th month ofpost partumperiod respectively, when AVPcAbs disappeared, accompanied by post-pituitary function recovery, persisting until the end of the follow-up. The determination of AVPcAbs is advisable in patients with autoimmune diseases planning their pregnancy, because they could be considered good predictive markers of gestational orpost partumautoimmune CDI. The monitoring of AVPcAb titres and post-pituitary function during pregnancy in these patients may allow for an early diagnosis and an early replacement therapy, which could induce the disappearance of these antibodies with consequent complete remission of CDI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|